Amgen Inc. (AMGN) Stock Analysis
Is AMGN a good investment?
Amgen Inc. (AMGN) has a Plutrex AI rating of 50.0/100 as of May 26, 2026, indicating a Hold consensus. The stock is not classified as halal-compliant. Key strength: Exceptional profitability with ROE 101.3% and industry-leading margins across all metrics. Main concern: Extreme leverage with debt-to-equity 5.65 creating 357% more financial risk than industry peers.
Investment Summary
AMGN presents a challenging investment case with exceptional profitability (ROE 101.3%, gross margin 71.5%) offset by severe structural concerns. The debt-to-equity ratio of 5.65 creates extreme leverage risk (357% above industry average), while forward EPS growth of only 4.7% next year represents a 98.1% underperformance versus industry peers. The PEG ratio of 3.79 indicates significant overvaluation despite trading at a 17.6% PE discount to peers. Recent Japanese safety concerns with Tavneos add regulatory risk, though authorities have reversed their prescription ban.
Key Strengths
- Exceptional profitability with ROE 101.3% and industry-leading margins across all metrics
- Strong cash generation with $7.4B free cash flow and $12B total cash providing operational flexibility
- Attractive PE valuation at 17.6% discount to industry average despite premium fundamentals
Key Concerns
- Extreme leverage with debt-to-equity 5.65 creating 357% more financial risk than industry peers
- Severe growth weakness with forward EPS growth 4.7% next year, 98.1% below industry average
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
AMGN shows stark contrasts across fundamentals. Profitability metrics are exceptional: ROE 101.3% (though leverage-inflated), gross margin 71.5% vs industry 69.98%, operating margin 33.8% vs industry 33.4%, and net margin 20.9% vs industry 18.9%. However, financial health is concerning with debt-to-equity 5.65 vs industry 1.24, creating significant leverage risk. Growth is the critical weakness: forward EPS growth 4.7% vs industry 252.6%, and 5-year growth 3.8% vs industry 8.4%. The PEG ratio of 3.79 indicates severe overvaluation for the growth profile. Free cash flow of $7.4B and cash of $12B provide liquidity but don't offset structural concerns. Additional metrics: PE Ratio: 23.60
News Sentiment
Amgen faces a complex mix of operational changes and safety concerns that highlight both stability and risk in its business model. The biotech giant recently announced CFO Peter Griffith's retirement, with Dittrich named as his successor, signaling planned leadership transition during a challenging period. More concerning are developments in Japan, where twenty deaths have been linked to Amgen's rare immune-disease drug Tavneos, creating significant regulatory scrutiny. However, Japanese authorities have reversed their earlier recommendation against prescribing the drug to new patients, suggesting the safety review may be stabilizing. On the positive side, Amgen is investing an additional $300 million in Puerto Rico manufacturing expansion, demonstrating confidence in its production capabilities and long-term growth strategy. These mixed developments reflect a company managing both growth investments and safety challenges while navigating leadership changes, creating uncertainty for investors about near-term execution and regulatory risk management.
Risk Assessment
Primary risks include extreme leverage (debt-to-equity 5.65) creating financial instability, severe growth deceleration making current valuation unsustainable, and ongoing Japanese regulatory concerns with Tavneos. Mitigation requires significant price discount to entry range $285-$295, representing 16-19% below current price to compensate for structural risks.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is AMGN a halal stock?
No, Amgen Inc. (AMGN) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for AMGN?
Amgen Inc. (AMGN) has a Plutrex AI rating of 50.0/100 with a Hold consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is AMGN a good investment?
According to Plutrex AI, AMGN has a Hold rating (50.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in AMGN?
US stocks like AMGN can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in AMGN?
Plutrex AI identifies the main risks for AMGN by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.